Prolonged correction of serum phosphorus in adults with x-linked hypophosphatemia using monthly doses of KRN23

Journal of Clinical Endocrinology and Metabolism

Volumn 100, Issue 7, 2015, Pages 2565-2573

  Imel, Erik A ^a   Zhang, Xiaoping ^b   Ruppe, Mary D ^c   Weber, Thomas J ^d   Klausner, Mark A ^b   Ito, Takahiro ^b   Vergeire, Maria ^b   Humphrey, Jeffrey S ^b   Glorieux, Francis H ^e   Portale, Anthony A ^f   Insogna, Karl ^g   Peacock, Munro ^a   Carpenter, Thomas O ^g  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b KYOWA HAKKO KOGYO CO LTD   (Japan)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e SHRINERS HOSPITAL FOR CHILDREN   (Canada)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE BONE ISOENZYME; CALCITRIOL; CALCIUM; CARBOXY TERMINAL TELOPEPTIDE; CREATININE; FIBROBLAST GROWTH FACTOR 23; KRN 23; OSTEOCALCIN; PHOSPHATE; PROCOLLAGEN C PROTEINASE; RECOMBINANT ANTIBODY; UNCLASSIFIED DRUG; FIBROBLAST GROWTH FACTOR; IMMUNOGLOBULIN G; KRN23 MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY; PHOSPHORUS; RECOMBINANT PROTEIN;

ADULT; AGED; ARTHRALGIA; ARTICLE; BACKACHE; CALCIUM EXCRETION; CALCIUM URINE LEVEL; CLINICAL ARTICLE; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG SAFETY; FEMALE; GLOMERULUS FILTRATION RATE; HEADACHE; HUMAN; HYPERCALCEMIA; HYPOCALCEMIA; INJECTION SITE URTICARIA; KIDNEY TUBULE ABSORPTION; LIMB PAIN; LONG TERM CARE; MALE; MULTICENTER STUDY; OPEN STUDY; OSTEOMALACIA; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RENAL TUBULAR MAXIMUM REABSORPTION RATE OF PHOSPHATE GLOMERULAR FILTRATION RATE; RHINOPHARYNGITIS; RICKETS; SIDE EFFECT; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION; X LINKED HYPOPHOSPHATEMIC RICKETS; BLOOD; CLINICAL TRIAL; DRUG ADMINISTRATION; DRUG EFFECTS; FAMILIAL HYPOPHOSPHATEMIC RICKETS; IMMUNOLOGY; MIDDLE AGED; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; AGED; ANTIBODIES, MONOCLONAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FAMILIAL HYPOPHOSPHATEMIC RICKETS; FEMALE; FIBROBLAST GROWTH FACTORS; GLOMERULAR FILTRATION RATE; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PHOSPHORUS; RECOMBINANT PROTEINS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84944461993     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2015-1551     Document Type: Article

References (30)

1. Burnett CH, Dent CE, Harper C, Warland BJ. Vitamin D-resistant rickets. Analysis of twenty-four pedigrees with hereditary and sporadic cases. Am J Med. 1964;36:222-232.
2. Imel EA, Econs MJ. Fibroblast growth factor 23: roles in health and disease. J Am Soc Nephrol. 2005;16:2565-2575.
3. Liu S, Quarles LD. Howfibroblast growth factor 23 works. JAmSoc Nephrol. 2007;18(6):1637-1647.
4. Larsson T, Marsell R, Schipani E, et al. Transgenic mice expressing fibroblast growth factor 23 under the control of the1(I) collagen promoter exhibit growth retardation, osteomalacia, and disturbed phosphate homeostasis. Endocrinology. 2004;145:3087-3094.
5. Shimada T, Urakawa I, Yamazaki Y, et al. FGF-23 transgenic mice demonstrate hypophosphatemic rickets with reduced expression of sodium phosphate cotransporter type IIa. Biochem Biophys Res Commun. 2004;314:409-414.
6. Gattineni J, Bates C, Twombley K, et al. FGF23 decreases renal NaPi-2a and NaPi-2c expression and induces hypophosphatemia in vivo predominantly via FGF receptor 1. AmJ Physiol Renal Physiol. 2009;297:F282-F291.
7. Haussler M, Hughes M, Baylink D, Littledike ET, Cork D, Pitt M. Influence of phosphate depletion on the biosynthesis and circulating level of 1-,25-dihydroxyvitamin D. Adv Exp Med Biol. 1977;81: 233-250.
8. Glorieux FH, Marie PJ, Pettifor JM, Delvin EE. Bone response to phosphate salts, ergocalciferol, and calcitriol in hypophosphatemic vitamin D-resistant rickets. N Engl J Med. 1980;303:1023-1031.
9. Harrell RM, Lyles KW, Harrelson JM, Friedman NE, Drezner MK. Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol. J Clin Invest. 1985;75:1858-1868.
10. Petersen DJ, Boniface AM, Schranck FW, Rupich RC, Whyte MP. X-linked hypophosphatemic rickets: a study (with literature review) of linear growth response to calcitriol and phosphate therapy. J Bone Miner Res. 1992;7:583-597.
11. Costa T, Marie PJ, Scriver CR, et al. X-linked hypophosphatemia: effect of calcitriol on renal handling of phosphate, serum phosphate, and bone mineralization. J Clin Endocrinol Metab. 1981;52:463-472.
12. Carpenter TO, Imel EA, Holm IA, Jan de Beur SM, Insogna KL. A clinician's guide to X-linked hypophosphatemia. J Bone Miner Res. 2011;26(7):1381-1388.
13. Yamazaki Y, Tamada T, Kasai N, et al. Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. J Bone Miner Res. 2008;23(9):1509-1518.
14. Aono Y, Yamazaki Y, Yasutake J, et al. Therapeutic effects of anti-FGF23 antibodies in hypophosphatemic rickets/osteomalacia. J Bone Miner Res. 2009;24:1879-1888.
15. Carpenter TO, Imel EA, Ruppe MD, et al. Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia. J Clin Invest. 2014;124:1587-1597.
16. Zhang X, Carpenter T, Imel E, et al. Pharmacokinetics and pharmacodynamics of a human monoclonal anti-FGF23 antibody (KRN23) after single-dose administration to patients with X-linked hypophosphatemia. J Bone Miner Res. 2013;28(suppl 1)SU0169.
17. Endo I, Fukumoto S, Ozono K, et al. Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement. Bone. 2008;42(6):1235-1239.
18. Payne RB. Renal tubular reabsorption of phosphate (TmP/GFR): indications and interpretation. Ann Clin Biochem. 1998;35:201-206.
19. National Cancer Institute. CommonTerminology Criteria for Adverse Events version 4. 03 (CTCAE). http://evs. nci. nih. gov/ftp1/CTCAE/ CTCAE-4. 03-2010-06-14-QuickReference-5x7. pdf. Published June 14, 2010.
20. Yamazaki Y, Okazaki R, ShibataM,et al. Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia. J Clin Endocrinol Metab. 2002; 87(11):4957-4960.
21. Quest Investigator Manual for theKyowaHakkoKirin Pharma, Inc. Trial: A Phase I/II, Open-Label, Repeat-Dose, Dose-Escalation Study of KRN23 in Adult Subjects With X-Linked Hypophosphatemia. Revision 1. 4, Valencia, CA: Quest Diagnostics; August 16, 2011.
22. Walton RJ, Bijvoet OL. Nomogramfor derivation of renal threshold phosphate concentration. Lancet. 1975;2(7929):309-310.
23. Investigator Laboratory Instruction Manual for Kirin Pharma. Esoterix Clinical Trials Services. Cranford, NJ: Esoterix; October 28, 2008.
24. National Institutes of Health. Creatinine clearance test. http:// www. nlm. nih. gov/medlineplus/ency/article/003611. htm. Accessed October 21, 2014.
25. Zhang X, Imel EA, Ruppe MD, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) following four monthly doses of a human monoclonal anti-FGF23 (Fibroblast Growth Factor 23) antibody (KRN23) in adults with X-linked hypophosphatemia (XLH). In: Proceedings from The Endocrine Society's 96th Annual Meeting and Expo; June 21-24, 2014; Chicago, IL. Abstract MON-0206.
26. Zhang X, Imel EA, Ruppe MD, et al. Pharmacokinetics (PK) and pharmacodynamics (PD) of a human anti-FGF23 antibody (KRN23) in a long-term extension study of adults with X-linked hypophosphatemia (XLH). J Bone Miner Res. 2014;29(suppl 1): S483.
27. Gundberg CM, Cole DE, Lian JB, Reade TM, Gallop PM. Serum osteocalcin in the treatment of inherited rickets with 1,25-dihydroxyvitamin D3. J Clin Endocrinol Metab. 1983;56:1063-1067.
28. Halliburton SS, Stillman AE, White RD. Noninvasive quantification of coronary artery calcification: methods and prognostic value. Cleve Clin J Med. 2002;69(suppl 3):S6-S11.
29. Moltz KC, Friedman AH, Nehgme RA, Kleinman CS, Carpenter TO. Ectopic cardiac calcification associated with hyperparathyroidism in a boy with hypophosphatemic rickets. Curr Opin Pediatr. 2001;13(4):373-375.
30. Ruppe MD, Zhang X, Imel EA, et al. Effect of four monthly doses of a human monoclonal anti-FGF23 (Fibroblast Growth Factor 23) antibody (KRN23) on quality of life in X-linked hypophosphatemia (XLH). In: Proceedings from The Endocrine Society's 96th Annual Meeting and Expo; June 21-24, 2014; Chicago, IL. AbstractMON-2010.